Floatz logo

Peluntamig

Small Cell Lung Cancer (SCLC)

Phanes TherapeuticsPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the Small Cell Lung Cancer (SCLC) cohort.

Asset / SponsorPhaseRating
Enzalutamide
MacroGenics
Phase 2B
Tas-102
Taiho Oncology, Inc.
Phase 2CCC
DESIPRAMINE
Joel Neal
Phase 2CCC
Bemotuzumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
Eb-Dart-Nk01
Beijing Biotech
Phase 1/2CC

View all 20 →

Same molecule, other indications

Peluntamig is also rated in:

Neuroendocrine Carcinomas (NEC)Dormant
CCC
Indicative ·
48 / 100
View asset →
Large Cell Neuroendocrine Cancer (LCNEC)Dormant
CC
Indicative ·
47 / 100
View asset →
Neuroendocrine Prostate Cancer (NEPC)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →